Literature DB >> 2533589

Synthesis and regional mouse brain distribution of [11C]nisoxetine, a norepinephrine uptake inhibitor.

M S Haka1, M R Kilbourn.   

Abstract

Nisoxetine, a selective and high affinity (IC50 = 1 nM) inhibitor of NE reuptake, has been radiolabeled in high specific activity (greater than 600 Ci/mmol) by the alkylation of the nor-methyl precursor with [11C]CH3I. Synthetic yields are good (40-60% from [11C]methyl iodide, corrected for decay, 20 min synthesis), with the product purified by HPLC. In vivo studies of regional brain distribution in CD-1 mice show uptake and retention of tracer in the cortex, striatum, hypothalamus and thalamus, with the highest levels in the hypothalamus and cortex. Specific binding in the cortex and hypothalamus can be reduced by preadministration of 7 mg/kg i.v. unlabeled nisoxetine. The possible value of [11C]nisoxetine as a PET imaging agent is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533589     DOI: 10.1016/0883-2897(89)90160-8

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN: 0883-2897


  9 in total

1.  Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram.

Authors:  Magnus Schou; Judit Sóvágó; Victor W Pike; Balázs Gulyás; Klaus P Bøgesø; Lars Farde; Christer Halldin
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

2.  5-tert-Butyl-2-(4'-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABA A receptor radioligands.

Authors:  Xuehe Li; Yong-Woon Jung; Scott E Snyder; Joseph Blair; Philip S Sherman; Timothy Desmond; Kirk A Frey; Michael R Kilbourn
Journal:  Nucl Med Biol       Date:  2007-11-26       Impact factor: 2.408

3.  Norepinephrine transporter inhibitors and their therapeutic potential.

Authors:  Jia Zhou
Journal:  Drugs Future       Date:  2004-12       Impact factor: 0.148

4.  (R)-N-Methyl-3-(3'-[F]fluoropropyl)phenoxy)-3-phenylpropanamine (F-MFP3) as a potential PET imaging agent for norepinephrine transporter.

Authors:  Vivien L Nguyen; Rama Pichika; Paayal H Bhakta; Ritu Kant; Jogeshwar Mukherjee
Journal:  J Labelled Comp Radiopharm       Date:  2010-02-09       Impact factor: 1.921

5.  Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER.

Authors:  Gilles D Tamagnan; Eric Brenner; David Alagille; Julie K Staley; Colin Haile; Andrei Koren; Michelle Early; Ronald M Baldwin; Frank I Tarazi; Ross J Baldessarini; Nachwa Jarkas; Mark M Goodman; John P Seibyl
Journal:  Bioorg Med Chem Lett       Date:  2006-10-12       Impact factor: 2.823

6.  Functional characterization of dopamine and norepinephrine transport across the apical and basal plasma membranes of the human placental syncytiotrophoblast.

Authors:  Hana Horackova; Rona Karahoda; Veronika Vachalova; Helena Turkova; Cilia Abad; Frantisek Staud
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

7.  (R)-N-Methyl-3-(3-(125)I-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters.

Authors:  Balagopal Lakshmi; Mei-Ping Kung; Brian Lieberman; Jun Zhao; Rikki Waterhouse; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

Review 8.  Assessment of cardiac autonomic neuronal function using PET imaging.

Authors:  James T Thackeray; Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2013-02       Impact factor: 5.952

9.  In vivo characterization of a novel norepinephrine transporter PET tracer [18F]NS12137 in adult and immature Sprague-Dawley rats.

Authors:  Francisco R López-Picón; Anna K Kirjavainen; Sarita Forsback; Jatta S Takkinen; Dan Peters; Merja Haaparanta-Solin; Olof Solin
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.